Skip to main content
INmune Bio, Inc. (INMB)
NASDAQ: INMB · IEX Real-Time Price · USD
11.57
+0.44 (3.95%)
At close: May 3, 2024, 4:00 PM
11.00
-0.57 (-4.93%)
After-hours: May 3, 2024, 5:57 PM EDT

INmune Bio Revenue

In the year 2023, INmune Bio had annual revenue of $155.00K, a decrease of -58.56%. Revenue in the quarter ending December 31, 2023 was $28.00K, a -71.13% decrease year-over-year.

Revenue (ttm)
$155.00K
Revenue Growth
-58.56%
P/S Ratio
1,475.06
Revenue / Employee
$14,091
Employees
11
Market Cap
228.63M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023155.00K-219.00K-58.56%
Dec 31, 2022374.00K193.00K106.63%
Dec 31, 2021181.00K170.00K1,545.45%
Dec 31, 202011.00K--
Dec 31, 20190--
Dec 31, 20180--
Dec 31, 20170--
Dec 31, 20160--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
AVITA Medical 51.57M
Metagenomi 44.76M
uniQure 15.84M
Cellectis 9.19M
Adlai Nortye 5.00M
Ovid Therapeutics 391.70K
Revenue Rankings

INMB News

More News